<!DOCTYPE html>
<html lang="zh-CN">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=5.0">
    <title>ç§‘ç ”æ—¥æŠ¥ - 2025-12-03</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", Arial, "Noto Sans", sans-serif, "Apple Color Emoji", "Segoe UI Emoji";
            line-height: 1.8;
            color: #2c3e50;
            background: linear-gradient(135deg, #f5f7fa 0%, #c3cfe2 100%);
            padding: 15px;
            font-size: 16px;
        }

        .container {
            max-width: 900px;
            margin: 0 auto;
            background: white;
            padding: 35px;
            border-radius: 16px;
            box-shadow: 0 10px 40px rgba(0,0,0,0.1);
        }

        /* æ ‡é¢˜ä¼˜åŒ– */
        h1 {
            color: #1a202c;
            font-size: 2em;
            border-bottom: 4px solid #667eea;
            padding-bottom: 15px;
            margin-bottom: 25px;
            font-weight: 700;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
        }

        h2 {
            color: #2d3748;
            font-size: 1.5em;
            margin-top: 40px;
            margin-bottom: 20px;
            padding-left: 15px;
            border-left: 5px solid #667eea;
            font-weight: 600;
        }

        h3 {
            color: #4a5568;
            font-size: 1.25em;
            margin-top: 28px;
            margin-bottom: 14px;
            font-weight: 600;
        }

        /* åˆ†ç±»æµè§ˆæŠ˜å åŠŸèƒ½ */
        details {
            margin: 20px 0;
            border-radius: 8px;
            overflow: hidden;
        }

        details summary {
            cursor: pointer;
            padding: 15px 20px;
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            color: #2d3748;
            font-size: 1.25em;
            font-weight: 600;
            text-align: right;
            direction: rtl;
            border-right: 5px solid #667eea;
            transition: all 0.3s ease;
            list-style: none;
            user-select: none;
        }

        details summary * {
            direction: ltr;
        }

        details summary::-webkit-details-marker {
            display: none;
        }

        details summary::before {
            content: 'â–¶';
            display: inline-block;
            margin-left: 10px;
            transition: transform 0.3s ease;
            font-size: 0.8em;
        }

        details[open] summary::before {
            transform: rotate(90deg);
        }

        details summary:hover {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            box-shadow: 0 4px 12px rgba(102, 126, 234, 0.3);
        }

        details[open] summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            border-right-color: white;
        }

        details .details-content {
            padding: 20px;
            background: white;
            border: 1px solid #e9ecef;
            border-top: none;
        }

        h4 {
            color: #718096;
            font-size: 1.1em;
            margin-top: 22px;
            margin-bottom: 12px;
            font-weight: 600;
        }

        p {
            margin-bottom: 16px;
            line-height: 1.8;
        }

        blockquote {
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            border-left: 4px solid #667eea;
            padding: 18px 22px;
            margin: 22px 0;
            border-radius: 8px;
            color: #4a5568;
            font-size: 0.95em;
            box-shadow: 0 2px 8px rgba(0,0,0,0.05);
        }

        blockquote p {
            margin-bottom: 8px;
        }

        blockquote p:last-child {
            margin-bottom: 0;
        }

        blockquote em {
            font-style: normal;
            color: #718096;
            font-size: 0.9em;
        }

        blockquote a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        blockquote a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* é¡¶éƒ¨ç½²åï¼ˆå±…å³ï¼‰ */
        .powered-by-top {
            text-align: right;
            font-size: 0.85em;
            color: #718096;
            font-style: italic;
            margin: 12px 0;
            padding-right: 5px;
        }

        .powered-by-top a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        .powered-by-top a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* AI æ€»ç»“åŒºåŸŸä¼˜åŒ– */
        .ai-summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 28px;
            border-radius: 16px;
            margin: 30px 0;
            box-shadow: 0 12px 35px rgba(102, 126, 234, 0.35);
            position: relative;
            overflow: hidden;
        }

        .ai-summary::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -50%;
            width: 200%;
            height: 200%;
            background: radial-gradient(circle, rgba(255,255,255,0.1) 0%, transparent 70%);
            pointer-events: none;
        }

        .ai-summary h2 {
            color: white;
            border-left: none;
            border-right: none;
            margin-top: 0;
            margin-bottom: 18px;
            padding-left: 15px;
            padding-right: 0;
            text-align: left;
            direction: ltr;
        }

        .ai-summary h3 {
            color: #f0f0f0;
            margin-top: 18px;
            border-right: 3px solid rgba(255,255,255,0.5);
            padding-right: 12px;
            padding-left: 0;
            text-align: right;
            direction: rtl;
        }

        .ai-summary h3 * {
            direction: ltr;
        }

        .ai-summary blockquote {
            background: rgba(255,255,255,0.15);
            border-left-color: white;
            color: white;
            backdrop-filter: blur(10px);
        }

        .ai-summary p {
            color: white;
        }

        .ai-summary strong {
            color: #fff;
            font-weight: 600;
        }

        ul, ol {
            margin-left: 28px;
            margin-bottom: 18px;
        }

        li {
            margin-bottom: 12px;
            line-height: 1.8;
        }

        /* é“¾æ¥ä¼˜åŒ– */
        a {
            color: #667eea;
            text-decoration: none;
            border-bottom: 1px solid transparent;
            transition: all 0.3s ease;
            font-weight: 500;
        }

        a:hover {
            border-bottom-color: #667eea;
            color: #764ba2;
        }

        /* è¡¨æ ¼ä¼˜åŒ– */
        table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
            box-shadow: 0 2px 12px rgba(0,0,0,0.08);
            border-radius: 10px;
            overflow: hidden;
        }

        th, td {
            border: 1px solid #e2e8f0;
            padding: 14px 18px;
            text-align: left;
        }

        th {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            font-weight: 600;
            font-size: 0.95em;
        }

        tr:nth-child(even) {
            background: #f8f9fa;
        }

        tr:hover {
            background: #e9ecef;
            transition: background 0.3s ease;
        }

        /* å…³é”®è¯ç»Ÿè®¡è¡¨æ ¼ç‰¹æ®Šæ ·å¼ï¼ˆæ›´ç´§å‡‘ï¼‰ */
        .keywords-table {
            font-size: 0.9em;
            max-width: 600px;
        }

        .keywords-table th,
        .keywords-table td {
            padding: 10px 14px;
        }

        .keywords-table th {
            font-size: 0.9em;
        }

        hr {
            border: none;
            border-top: 2px solid #e2e8f0;
            margin: 40px 0;
        }

        strong {
            color: #2d3748;
            font-weight: 600;
        }

        code {
            background: #f1f5f9;
            padding: 3px 8px;
            border-radius: 5px;
            font-family: "SF Mono", Monaco, Consolas, "Courier New", monospace;
            font-size: 0.9em;
            color: #e53e3e;
        }

        /* ç¾åŒ–æ»šåŠ¨æ¡ */
        ::-webkit-scrollbar {
            width: 8px;
            height: 8px;
        }

        ::-webkit-scrollbar-track {
            background: #f1f1f1;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb {
            background: #667eea;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb:hover {
            background: #764ba2;
        }

        /* ç§»åŠ¨ç«¯ä¼˜åŒ– */
        @media (max-width: 768px) {
            body {
                padding: 8px;
                font-size: 15px;
            }

            .container {
                padding: 22px 18px;
                border-radius: 12px;
            }

            h1 {
                font-size: 1.6em;
                padding-bottom: 12px;
                margin-bottom: 20px;
            }

            h2 {
                font-size: 1.3em;
                margin-top: 30px;
                padding-left: 12px;
            }

            h3 {
                font-size: 1.15em;
            }

            h4 {
                font-size: 1.05em;
            }

            blockquote {
                padding: 14px 16px;
                margin: 18px 0;
            }

            .ai-summary {
                padding: 20px;
                margin: 22px 0;
            }

            .ai-summary-header {
                flex-direction: column;
                align-items: flex-start;
            }

            .powered-by {
                margin-left: 0;
                margin-top: 8px;
            }

            table {
                font-size: 0.85em;
            }

            th, td {
                padding: 10px 12px;
            }

            .keywords-table {
                font-size: 0.8em;
            }

            .keywords-table th,
            .keywords-table td {
                padding: 8px 10px;
            }

            ul, ol {
                margin-left: 22px;
            }
        }

        /* è¶…å°å±å¹• */
        @media (max-width: 480px) {
            body {
                font-size: 14px;
                padding: 5px;
            }

            .container {
                padding: 18px 14px;
            }

            h1 {
                font-size: 1.4em;
            }

            h2 {
                font-size: 1.2em;
            }

            .ai-summary {
                padding: 16px;
            }

            .powered-by {
                font-size: 0.7em;
            }
        }

        /* å¹³æ»‘æ»šåŠ¨ */
        html {
            scroll-behavior: smooth;
        }

        /* æé«˜å¯ç‚¹å‡»åŒºåŸŸ */
        @media (pointer: coarse) {
            a {
                padding: 4px 0;
                display: inline-block;
            }
        }

        /* æ‰“å°ä¼˜åŒ– */
        @media print {
            body {
                background: white;
                padding: 0;
            }

            .container {
                box-shadow: none;
                max-width: 100%;
            }

            .ai-summary {
                background: #f5f5f5;
                color: black;
                box-shadow: none;
            }

            .ai-summary h2,
            .ai-summary h3,
            .ai-summary p,
            .ai-summary strong {
                color: black;
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <h1>ğŸ“… Daily Report - 2025-12-03</h1>
<blockquote>
<p>ä»Šæ—¥ç­›é€‰å‡º <strong>88</strong> æ¡å†…å®¹ï¼Œæ¥è‡ª <strong>3</strong> ä¸ªæ¥æº</p>
</blockquote>
<div class="powered-by-top">Powered by <a href="https://kyplus.de" target="_blank" rel="noopener noreferrer">ç§‘ç ”æ™®æ‹‰æ–¯</a> & <a href="https://claude.ai" target="_blank" rel="noopener noreferrer">Claude</a></div>

<hr />
<div class="ai-summary">
                <h2>ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“</h2>
                <h3>ğŸ§¬ æ•°æ®å‰æ²¿</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
KMT2Dåœ¨å»åŠ¿æŠµæŠ—æ€§å‰åˆ—è…ºç™Œï¼ˆCRPCï¼‰ä¸­ä»‹å¯¼è°±ç³»å¯å¡‘æ€§å’Œæ²»ç–—ååº”ï¼Œæ­ç¤ºäº†å…¶ä½œä¸ºå…³é”®è°ƒæ§å› å­çš„æ–°ä½œç”¨ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
*   <strong>è‚¿ç˜¤å…ç–«ä¸æ²»ç–—</strong>ï¼šåˆæˆé½å¢©æœçƒ·ä¸‰èœç±»åŒ–åˆç‰©é€šè¿‡è¯±å¯¼æŠ—è‚¿ç˜¤å…ç–«ååº”ï¼Œæœ‰æ•ˆæŠ‘åˆ¶è‚¿ç˜¤ç”Ÿé•¿ï¼Œä¸”ä¸ä¾èµ–äºKEAP1çªå˜çŠ¶æ€ã€‚<br />
*   <strong>åŸºå› è°ƒæ§ä¸ç–¾ç—…</strong>ï¼šKMT2Dé€šè¿‡å½±å“CRPCçš„è°±ç³»å¯å¡‘æ€§åŠå¯¹æ²»ç–—çš„ååº”ï¼›CBLåŸºå› ç¼ºé™·å½±å“Bç»†èƒå‘è‚²ä¸åŠŸèƒ½ï¼›NKX2-1è½¬å½•å› å­ä¸RUNX1ååŒä¿æŠ¤T-ALLç»†èƒå…å—DNAæŸä¼¤ã€‚<br />
*   <strong>ç¥ç»é€€è¡Œæ€§ç–¾ç—…</strong>ï¼šçº¿ç²’ä½“DNAè€—ç«­çš„ç¥ç»å…ƒç»†èƒè½¬å½•ç»„å­¦å˜åŒ–æ­ç¤ºä¸é˜¿å°”èŒ¨æµ·é»˜ç—…ç›¸å…³çš„é€šè·¯æ”¹å˜ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
*   <strong>å¤šç»„å­¦æ•´åˆåˆ†æ</strong>ï¼šç»“åˆChIP-seqã€ATAC-seqå’ŒBulk RNA-seqç­‰æŠ€æœ¯ï¼Œæ·±å…¥è§£æCRPCä¸­KMT2Dçš„åŠŸèƒ½æœºåˆ¶ã€‚<br />
*   <strong>å•ç»†èƒæµ‹åº</strong>ï¼šåº”ç”¨äºæ¯›ç»†èƒç™½è¡€ç—…ã€é»‘è‰²ç´ ç˜¤æ·‹å·´ç»“åŠçŒªè„‚è‚ªç»„ç»‡ï¼Œæä¾›é«˜åˆ†è¾¨ç‡çš„ç»†èƒå¼‚è´¨æ€§ä¿¡æ¯ã€‚</p>
<h3>ğŸ”¬ æœŸåˆŠæ–‡ç« </h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
é¦–æ¬¡é˜æ˜ç»å¯¹æ·‹å·´ç»†èƒï¼ˆALCï¼‰è®¡æ•°å‡é«˜ä¸æ…¢æ€§æ·‹å·´ç»†èƒç™½è¡€ç—…ï¼ˆCLLï¼‰çš„ç»å¯¹é£é™©å…³ç³»ï¼Œå¹¶æå‡ºæ–°å‹åŸºå› ç»„æ£€æµ‹HER2DXæ”¯æŒHER2é˜³æ€§ä¹³è…ºç™Œæ²»ç–—å†³ç­–ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- è¯„ä¼°ALCè®¡æ•°ã€å¹´é¾„ã€æ€§åˆ«å¯¹CLLç»å¯¹é£é™©çš„å½±å“ã€‚<br />
- æ¢ç©¶HER2DXåŸºå› ç»„æ£€æµ‹ä¸HER2é˜³æ€§ä¹³è…ºç™Œç”Ÿç‰©å­¦ç‰¹å¾åŠæ–°è¾…åŠ©æ²»ç–—ååº”çš„å…³ç³»ã€‚<br />
- è¯„ä¼°PIK3CAçªå˜HER2é˜³æ€§è½¬ç§»æ€§ä¹³è…ºç™Œä¸€çº¿æ²»ç–—åï¼Œipatasertibè”åˆåŒé‡æŠ—HER2ç»´æŒæ²»ç–—çš„å®‰å…¨æ€§ä¸å¯è¡Œæ€§ã€‚<br />
- ç ”ç©¶çº¦ç¿°é€Šä¹³é…¸æ†èŒå¦‚ä½•åˆ©ç”¨èƒ†æ±é…¸å’Œæ´»æ€§æ°§æŠ‘åˆ¶é«˜è„‚é¥®é£Ÿè¯±å¯¼çš„ç»“ç›´è‚ ç™Œã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- åˆ©ç”¨è‹±å›½ç”Ÿç‰©æ ·æœ¬åº“å¤§è§„æ¨¡çºµå‘æ•°æ®è¿›è¡ŒCLLé£é™©åˆ†æã€‚<br />
- éªŒè¯HER2DXåŸºå› ç»„æ£€æµ‹åœ¨HER2é˜³æ€§ä¹³è…ºç™Œæ²»ç–—å†³ç­–ä¸­çš„åº”ç”¨ã€‚<br />
- 1bæœŸä¸´åºŠè¯•éªŒè¯„ä¼°æ–°å‹AKTæŠ‘åˆ¶å‰‚ipatasertibçš„è”åˆæ²»ç–—æ–¹æ¡ˆã€‚</p>
<h3>ğŸ§ª åšå®¢æ›´æ–°</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
RNAæµ‹åºæ­ç¤ºä¹³è…ºç™Œè‚¿ç˜¤å¼‚è´¨æ€§ä¸ç»†èƒç”Ÿé•¿ã€å…ç–«æ´»æ€§ç›¸å…³ï¼Œä¸ºè‚¿ç˜¤å¾®ç¯å¢ƒç ”ç©¶æä¾›æ–°è§†è§’ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- è¯„ä¼°ä¹³è…ºç™Œè‚¿ç˜¤å¼‚è´¨æ€§<br />
- æ¢ç´¢è‚¿ç˜¤å¼‚è´¨æ€§ä¸ç»†èƒç”Ÿé•¿ã€å…ç–«æ´»æ€§çš„å…³è”</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- åº”ç”¨RNAæµ‹åºæŠ€æœ¯åˆ†æè‚¿ç˜¤æ ·æœ¬</p>
<p><strong>ç²¾ç‚¼æ€»ç»“</strong>ï¼š<br />
ä»Šæ—¥åšå®¢æ›´æ–°èšç„¦äºä¸€é¡¹åˆ©ç”¨RNAæµ‹åºæŠ€æœ¯è¯„ä¼°ä¹³è…ºç™Œè‚¿ç˜¤å¼‚è´¨æ€§çš„ç ”ç©¶ã€‚è¯¥ç ”ç©¶æ­ç¤ºäº†è‚¿ç˜¤å¼‚è´¨æ€§ä¸ç»†èƒç”Ÿé•¿å’Œå…ç–«æ´»æ€§ä¹‹é—´å­˜åœ¨é‡è¦å…³è”ï¼Œä¸ºç†è§£è‚¿ç˜¤å¾®ç¯å¢ƒçš„å¤æ‚æ€§æä¾›äº†æ–°çš„è¯æ®ã€‚å°½ç®¡åœ¨é¢„æµ‹æ²»ç–—ååº”æ–¹é¢èƒ½åŠ›æœ‰é™ï¼Œä½†è¿™é¡¹å·¥ä½œé€šè¿‡ç²¾ç¡®çš„åˆ†å­è¡¨å¾ï¼Œä¸ºæœªæ¥æ›´æ·±å…¥åœ°ç ”ç©¶è‚¿ç˜¤å¼‚è´¨æ€§åŠå…¶å¯¹ç™Œç—‡å‘å±•çš„å½±å“å¥ å®šäº†åŸºç¡€ã€‚</p>
            </div><h2>ğŸ“š åˆ†ç±»æµè§ˆ</h2>
<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§¬ æ•°æ®å‰æ²¿ (83æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰</h4>
<p><strong>1.</strong> â­ <strong>GSE309664 çº¿ç²’ä½“DNAè€—ç«­ç¥ç»å…ƒç»†èƒçš„å…¨å±€è½¬å½•ç»„å˜åŒ–æ­ç¤ºäº†é˜¿å°”èŒ¨æµ·é»˜ç—…ç›¸å…³é€šè·¯çš„å˜åŒ–</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šAlzheimerã€Neuronalã€pathway<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Blaise W Menta ; Emily Schueddig ; Amol Ranjan ; Yanming Li ; Heather M Wilkins ; Dong Pei ; Russell H SwerdlowSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensBackground: Mitochondrial dysfunction, a prominent feature of Alzheimerâ€™s disease (AD), could represent a cause or consequence of the disease. Objective: We determined the extent to which mitochondrial dysfunction due to mitochondrial DNA (mtDNA) depletion induces transcription changes that link to AD phenomena. Methods: We performed a transcriptomic survey of human neuronal SH SY5Y and NTERA 2/NT2 mtDNA-depleted (Ï0) and intact (Ï+) cell lines. Differentially expressed genes (DEGs) between SH-SY5Y or NT2 Ï0 and Ï+ cells were identified using edgeR, and we used the Equivalent Change Index (ECI) approach to quantify concordant DEG behavior across the cell lines. Gene set enrichment and over representation analysis (GSEA; ORA) were used to determine impact on the KEGG Alzheimerâ€™s and other neurodegenerative disease pathways, ascertain pathway and term enrichment in the Reactome and Gene Ontology databases, and generate activation z-scores in the Ingenuity Pathway Analysis (IPA) database. Results: Relative to their Ï+ comparators, Ï0 lines differentially expressed &gt;75% of their genes, and &gt;20% more than doubled or halved expression. The KEGG Alzheimerâ€™s pathway was significantly enriched, and ECI-identified genes ranked the Alzheimerâ€™s, Parkinsonâ€™s, ALS, and Huntingtonâ€™s KEGG pathways among the most enriched gene sets. There was broad enrichment of pathways and terms relating to AD phenomena, which reflected lipid, insulin signaling, inflammation/immune response, synapse, endosome/endocytosis, RNA, and proteostasis biology. Conclusion: In neuronal cell lines, mitochondrial dysfunction due to mtDNA depletion alters gene expression in ways that recapitulate or predictably promote AD molecular phenomena.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309664" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> â­ <strong>GSE308273 åˆæˆé½å¢©æœçƒ·ä¸‰èœç±»åŒ–åˆç‰©å¯æŠ‘åˆ¶è‚¿ç˜¤ç”Ÿé•¿å¹¶ä¿ƒè¿›æŠ—è‚¿ç˜¤å…ç–«ååº”ï¼Œä¸”è¯¥ä½œç”¨ç‹¬ç«‹äºç™Œç—‡KEAP1çªå˜çŠ¶æ€</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€cancerã€immune<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Christopher J Occhiuto ; Jessica A Moerland ; Karen T Liby ; Ana S LealSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusKEAP1 negatively regulates the cytoprotective factor NRF2 and is commonly inactivated in lung cancer cells. Loss of function KEAP1 mutations in cancer cells contribute to NRF2 activation and tumor immune evasion through immunosuppression and drug resistance. Counterintuitively, treatment with synthetic oleanane triterpenoids, potent NRF2 activa-tors, reduces preclinical tumor burden. This suggests the functional target of these drugs in cancer models is not the cancer cells but another tumor immune microenvironment (TIME) cell population. The anti-tumor potential of cells within the TIME, particularly macrophages, is potentiated by triterpenoid treatment in cancers with wild-type KEAP1 status. As KEAP1-mutant cancers show reduced tumor immune responses, triterpenoid-mediated immune stimulation may particularly benefit these cases, but this has not been investigated. To characterize the immunomodulatory effects of triterpenoids in KEAP1-mutant lung cancer, we studied tumor-educated bone marrow-derived macrophages (TE-BMDMs) and lung cancer models treated with the triterpenoids CDDO-Me or omaveloxolone. RNA-sequencing of TE-BMDMs cultured in KEAP1 KO compared to WT cancer-conditioned media had enhanced tumor-promoting phenotypes which reversed with CDDO-Me treatment. Similarly, subcutaneous KEAP1 KO tumors were larger and more immune-suppressed compared to WT tumors. Both CDDO-Me and omaveloxolone reduced tumor burden and improved immune cell phenotypes within the TIME, independent of KEAP1 mutational status.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE308273" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> â­ <strong>GSE308945 ç»„è›‹ç™½ç”²åŸºè½¬ç§»é…¶ KMT2D æ˜¯å»åŠ¿æŠµæŠ—æ€§å‰åˆ—è…ºç™Œè°±ç³»å¯å¡‘æ€§å’Œæ²»ç–—ååº”çš„å…³é”®ä»‹è´¨ [FOSL1 ChIP-Seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€ChIP-seqã€histone<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Eneda Toska ; Wouter Karthaus ; Srushti Kittane ; Erik Ladewig ; Taibo Li ; Yangzhenyu GaoSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiensCastration-resistant prostate cancer (CRPC) is largely dependent on the androgen receptor (AR) for growth and often exhibits hyperactive PI3K signaling, most frequently due to PTEN loss. Therapeutic pressure from anti-AR therapies can induce trans-differentiation toward an AR-independent phenotype. Recently, different subtypes of AR-independent CRPC have been redefined, with the stem cell-like (SCL) subtype emerging as one of the most prevalent. Elucidation of the epigenetic mechanisms controlling the maintenance of these distinct CRPC cell states could pave the way for effective combinatorial therapies for CRPC. In this study, we identified a key role for the histone methyltransferase KMT2D in establishing the chromatin competence necessary for the recruitment of AR and FOXA1 transcription factors (TFs) that are essential for the AR transcriptional output in AR-dependent CRPC cell lines, patient derived organoids, and patient samples. Unexpectedly, KMT2D maintained the identity of the AR-low CRPC-SCL subtype and controlled activity of AP-1 TFs such as FOSL1, which acts as a master regulator of this subtype. Single cell transcriptomics and chromatin assays underscored the role of KMT2D in sustaining a mixed lineage cell state via AP-1 and FOXA1. The combined suppression of PI3K/AKT and KMT2D reduced cell proliferation in prostate cancer cells and patient-derived organoids in both CRPC-AR and CRPC-SCL subtypes. Altogether, these results unveil KMT2D as a major mediator of the epigenetic landscape in subtype-specific CRPC, contributing to tumor growth and therapeutic response.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE308945" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> â­ <strong>GSE296116 ç»„è›‹ç™½ç”²åŸºè½¬ç§»é…¶ KMT2D æ˜¯å»åŠ¿æŠµæŠ—æ€§å‰åˆ—è…ºç™Œè°±ç³»å¯å¡‘æ€§å’Œæ²»ç–—ååº”çš„å…³é”®ä»‹è´¨ [MSKPCA3 Bulk RNA-Seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€RNA-seqã€histone<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Eneda Toska ; Wouter Karthaus ; Srushti Kittane ; Erik Ladewig ; Taibo LiSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensCastration-resistant prostate cancer (CRPC) is largely dependent on the androgen receptor (AR) for growth and often exhibits hyperactive PI3K signaling, most frequently due to PTEN loss. Therapeutic pressure from anti-AR therapies can induce trans-differentiation toward an AR-independent phenotype. Recently, different subtypes of AR-independent CRPC have been redefined, with the stem cell-like (SCL) subtype emerging as one of the most prevalent. Elucidation of the epigenetic mechanisms controlling the maintenance of these distinct CRPC cell states could pave the way for effective combinatorial therapies for CRPC. In this study, we identified a key role for the histone methyltransferase KMT2D in establishing the chromatin competence necessary for the recruitment of AR and FOXA1 transcription factors (TFs) that are essential for the AR transcriptional output in AR-dependent CRPC cell lines, patient derived organoids, and patient samples. Unexpectedly, KMT2D maintained the identity of the AR-low CRPC-SCL subtype and controlled activity of AP-1 TFs such as FOSL1, which acts as a master regulator of this subtype. Single cell transcriptomics and chromatin assays underscored the role of KMT2D in sustaining a mixed lineage cell state via AP-1 and FOXA1. The combined suppression of PI3K/AKT and KMT2D reduced cell proliferation in prostate cancer cells and patient-derived organoids in both CRPC-AR and CRPC-SCL subtypes. Altogether, these results unveil KMT2D as a major mediator of the epigenetic landscape in subtype-specific CRPC, contributing to tumor growth and therapeutic response.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296116" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>5.</strong> â­ <strong>GSE296115 ç»„è›‹ç™½ç”²åŸºè½¬ç§»é…¶ KMT2D æ˜¯å»åŠ¿æŠµæŠ—æ€§å‰åˆ—è…ºç™Œè°±ç³»å¯å¡‘æ€§å’Œæ²»ç–—ååº”çš„å…³é”®ä»‹è´¨ [LNCaP Bulk RNA-Seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€RNA-seqã€histone<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Eneda Toska ; Wouter Karthaus ; Srushti Kittane ; Erik Ladewig ; Taibo LiSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensCastration-resistant prostate cancer (CRPC) is largely dependent on the androgen receptor (AR) for growth and often exhibits hyperactive PI3K signaling, most frequently due to PTEN loss. Therapeutic pressure from anti-AR therapies can induce trans-differentiation toward an AR-independent phenotype. Recently, different subtypes of AR-independent CRPC have been redefined, with the stem cell-like (SCL) subtype emerging as one of the most prevalent. Elucidation of the epigenetic mechanisms controlling the maintenance of these distinct CRPC cell states could pave the way for effective combinatorial therapies for CRPC. In this study, we identified a key role for the histone methyltransferase KMT2D in establishing the chromatin competence necessary for the recruitment of AR and FOXA1 transcription factors (TFs) that are essential for the AR transcriptional output in AR-dependent CRPC cell lines, patient derived organoids, and patient samples. Unexpectedly, KMT2D maintained the identity of the AR-low CRPC-SCL subtype and controlled activity of AP-1 TFs such as FOSL1, which acts as a master regulator of this subtype. Single cell transcriptomics and chromatin assays underscored the role of KMT2D in sustaining a mixed lineage cell state via AP-1 and FOXA1. The combined suppression of PI3K/AKT and KMT2D reduced cell proliferation in prostate cancer cells and patient-derived organoids in both CRPC-AR and CRPC-SCL subtypes. Altogether, these results unveil KMT2D as a major mediator of the epigenetic landscape in subtype-specific CRPC, contributing to tumor growth and therapeutic response.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296115" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>6.</strong> â­ <strong>GSE293211 ç»„è›‹ç™½ç”²åŸºè½¬ç§»é…¶ KMT2D æ˜¯å»åŠ¿æŠµæŠ—æ€§å‰åˆ—è…ºç™Œè°±ç³»å¯å¡‘æ€§å’Œæ²»ç–—ååº”çš„å…³é”®ä»‹è´¨ [MSKPCA2 Bulk RNA-seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€RNA-seqã€histone<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Eneda Toska ; Wouter Karthaus ; Srushti Kittane ; Erik Ladewig ; Taibo Li ; Wanlu ChenSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensCastration-resistant prostate cancer (CRPC) is largely dependent on the androgen receptor (AR) for growth and often exhibits hyperactive PI3K signaling, most frequently due to PTEN loss. Therapeutic pressure from anti-AR therapies can induce trans-differentiation toward an AR-independent phenotype. Recently, different subtypes of AR-independent CRPC have been redefined, with the stem cell-like (SCL) subtype emerging as one of the most prevalent. Elucidation of the epigenetic mechanisms controlling the maintenance of these distinct CRPC cell states could pave the way for effective combinatorial therapies for CRPC. In this study, we identified a key role for the histone methyltransferase KMT2D in establishing the chromatin competence necessary for the recruitment of AR and FOXA1 transcription factors (TFs) that are essential for the AR transcriptional output in AR-dependent CRPC cell lines, patient derived organoids, and patient samples. Unexpectedly, KMT2D maintained the identity of the AR-low CRPC-SCL subtype and controlled activity of AP-1 TFs such as FOSL1, which acts as a master regulator of this subtype. Single cell transcriptomics and chromatin assays underscored the role of KMT2D in sustaining a mixed lineage cell state via AP-1 and FOXA1. The combined suppression of PI3K/AKT and KMT2D reduced cell proliferation in prostate cancer cells and patient-derived organoids in both CRPC-AR and CRPC-SCL subtypes. Altogether, these results unveil KMT2D as a major mediator of the epigenetic landscape in subtype-specific CRPC, contributing to tumor growth and therapeutic response.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293211" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>7.</strong> â­ <strong>GSE293202 ç»„è›‹ç™½ç”²åŸºè½¬ç§»é…¶ KMT2D æ˜¯å»åŠ¿æŠµæŠ—æ€§å‰åˆ—è…ºç™Œè°±ç³»å¯å¡‘æ€§å’Œæ²»ç–—ååº”çš„å…³é”®ä»‹è´¨ [H3K4me2 ChIP-Seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€ChIP-seqã€histone<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Eneda Toska ; Wouter Karthaus ; Srushti Kittane ; Erik Ladewig ; Taibo LiSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiensCastration-resistant prostate cancer (CRPC) is largely dependent on the androgen receptor (AR) for growth and often exhibits hyperactive PI3K signaling, most frequently due to PTEN loss. Therapeutic pressure from anti-AR therapies can induce trans-differentiation toward an AR-independent phenotype. Recently, different subtypes of AR-independent CRPC have been redefined, with the stem cell-like (SCL) subtype emerging as one of the most prevalent. Elucidation of the epigenetic mechanisms controlling the maintenance of these distinct CRPC cell states could pave the way for effective combinatorial therapies for CRPC. In this study, we identified a key role for the histone methyltransferase KMT2D in establishing the chromatin competence necessary for the recruitment of AR and FOXA1 transcription factors (TFs) that are essential for the AR transcriptional output in AR-dependent CRPC cell lines, patient derived organoids, and patient samples. Unexpectedly, KMT2D maintained the identity of the AR-low CRPC-SCL subtype and controlled activity of AP-1 TFs such as FOSL1, which acts as a master regulator of this subtype. Single cell transcriptomics and chromatin assays underscored the role of KMT2D in sustaining a mixed lineage cell state via AP-1 and FOXA1. The combined suppression of PI3K/AKT and KMT2D reduced cell proliferation in prostate cancer cells and patient-derived organoids in both CRPC-AR and CRPC-SCL subtypes. Altogether, these results unveil KMT2D as a major mediator of the epigenetic landscape in subtype-specific CRPC, contributing to tumor growth and therapeutic response.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293202" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>8.</strong> â­ <strong>GSE293182 ç»„è›‹ç™½ç”²åŸºè½¬ç§»é…¶ KMT2D æ˜¯å»åŠ¿æŠµæŠ—æ€§å‰åˆ—è…ºç™Œè°±ç³»å¯å¡‘æ€§å’Œæ²»ç–—ååº”çš„å…³é”®ä»‹è´¨ [PC3 Bulk RNA-seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€RNA-seqã€histone<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Eneda Toska ; Wouter Karthaus ; Srushti Kittane ; Erik Ladewig ; Taibo Li ; Yangzhenyu GaoSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensCastration-resistant prostate cancer (CRPC) is largely dependent on the androgen receptor (AR) for growth and often exhibits hyperactive PI3K signaling, most frequently due to PTEN loss. Therapeutic pressure from anti-AR therapies can induce trans-differentiation toward an AR-independent phenotype. Recently, different subtypes of AR-independent CRPC have been redefined, with the stem cell-like (SCL) subtype emerging as one of the most prevalent. Elucidation of the epigenetic mechanisms controlling the maintenance of these distinct CRPC cell states could pave the way for effective combinatorial therapies for CRPC. In this study, we identified a key role for the histone methyltransferase KMT2D in establishing the chromatin competence necessary for the recruitment of AR and FOXA1 transcription factors (TFs) that are essential for the AR transcriptional output in AR-dependent CRPC cell lines, patient derived organoids, and patient samples. Unexpectedly, KMT2D maintained the identity of the AR-low CRPC-SCL subtype and controlled activity of AP-1 TFs such as FOSL1, which acts as a master regulator of this subtype. Single cell transcriptomics and chromatin assays underscored the role of KMT2D in sustaining a mixed lineage cell state via AP-1 and FOXA1. The combined suppression of PI3K/AKT and KMT2D reduced cell proliferation in prostate cancer cells and patient-derived organoids in both CRPC-AR and CRPC-SCL subtypes. Altogether, these results unveil KMT2D as a major mediator of the epigenetic landscape in subtype-specific CRPC, contributing to tumor growth and therapeutic response.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293182" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>9.</strong> â­ <strong>GSE293140 ç»„è›‹ç™½ç”²åŸºè½¬ç§»é…¶ KMT2D æ˜¯å»åŠ¿æŠµæŠ—æ€§å‰åˆ—è…ºç™Œè°±ç³»å¯å¡‘æ€§å’Œæ²»ç–—ååº”çš„å…³é”®ä»‹è´¨ [PC3 Bulk ATAC-seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€ATAC-seqã€histone<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Eneda Toska ; Wouter Karthaus ; Srushti Kittane ; Erik Ladewig ; Taibo Li ; Yangzhenyu GaoSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiensCastration-resistant prostate cancer (CRPC) is largely dependent on the androgen receptor (AR) for growth and often exhibits hyperactive PI3K signaling, most frequently due to PTEN loss. Therapeutic pressure from anti-AR therapies can induce trans-differentiation toward an AR-independent phenotype. Recently, different subtypes of AR-independent CRPC have been redefined, with the stem cell-like (SCL) subtype emerging as one of the most prevalent. Elucidation of the epigenetic mechanisms controlling the maintenance of these distinct CRPC cell states could pave the way for effective combinatorial therapies for CRPC. In this study, we identified a key role for the histone methyltransferase KMT2D in establishing the chromatin competence necessary for the recruitment of AR and FOXA1 transcription factors (TFs) that are essential for the AR transcriptional output in AR-dependent CRPC cell lines, patient derived organoids, and patient samples. Unexpectedly, KMT2D maintained the identity of the AR-low CRPC-SCL subtype and controlled activity of AP-1 TFs such as FOSL1, which acts as a master regulator of this subtype. Single cell transcriptomics and chromatin assays underscored the role of KMT2D in sustaining a mixed lineage cell state via AP-1 and FOXA1. The combined suppression of PI3K/AKT and KMT2D reduced cell proliferation in prostate cancer cells and patient-derived organoids in both CRPC-AR and CRPC-SCL subtypes. Altogether, these results unveil KMT2D as a major mediator of the epigenetic landscape in subtype-specific CRPC, contributing to tumor growth and therapeutic response.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293140" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>10.</strong> â­ <strong>GSE293101 ç»„è›‹ç™½ç”²åŸºè½¬ç§»é…¶ KMT2D æ˜¯å»åŠ¿æŠµæŠ—æ€§å‰åˆ—è…ºç™Œè°±ç³»å¯å¡‘æ€§å’Œæ²»ç–—ååº”çš„å…³é”®ä»‹è´¨ [KMT2D ChIP-seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€ChIP-seqã€histone<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Eneda Toska ; Wouter Karthaus ; Srushti Kittane ; Erik Ladewig ; Taibo LiSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiensCastration-resistant prostate cancer (CRPC) is largely dependent on the androgen receptor (AR) for growth and often exhibits hyperactive PI3K signaling, most frequently due to PTEN loss. Therapeutic pressure from anti-AR therapies can induce trans-differentiation toward an AR-independent phenotype. Recently, different subtypes of AR-independent CRPC have been redefined, with the stem cell-like (SCL) subtype emerging as one of the most prevalent. Elucidation of the epigenetic mechanisms controlling the maintenance of these distinct CRPC cell states could pave the way for effective combinatorial therapies for CRPC. In this study, we identified a key role for the histone methyltransferase KMT2D in establishing the chromatin competence necessary for the recruitment of AR and FOXA1 transcription factors (TFs) that are essential for the AR transcriptional output in AR-dependent CRPC cell lines, patient derived organoids, and patient samples. Unexpectedly, KMT2D maintained the identity of the AR-low CRPC-SCL subtype and controlled activity of AP-1 TFs such as FOSL1, which acts as a master regulator of this subtype. Single cell transcriptomics and chromatin assays underscored the role of KMT2D in sustaining a mixed lineage cell state via AP-1 and FOXA1. The combined suppression of PI3K/AKT and KMT2D reduced cell proliferation in prostate cancer cells and patient-derived organoids in both CRPC-AR and CRPC-SCL subtypes. Altogether, these results unveil KMT2D as a major mediator of the epigenetic landscape in subtype-specific CRPC, contributing to tumor growth and therapeutic response.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293101" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<blockquote>
<p>ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 73 æ¡å†…å®¹ï¼Œè¯¦è§ <a href="#æ›´å¤š-æ•°æ®å‰æ²¿">æ–‡æœ«</a></p>
</blockquote>
</div>
</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ”¬ æœŸåˆŠæ–‡ç«  (4æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨4æ¡ï¼‰</h4>
<p><strong>1.</strong> <strong>æ·‹å·´ç»†èƒè®¡æ•°åŠæ…¢æ€§æ·‹å·´ç»†èƒç™½è¡€ç—…é£é™©ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šæ·‹å·´<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: èƒŒæ™¯ ç»å¯¹æ·‹å·´ç»†èƒï¼ˆALCï¼‰è®¡æ•°å‡é«˜å¸¸è¢«ç”¨ä½œæ…¢æ€§æ·‹å·´ç»†èƒç™½è¡€ç—…ï¼ˆCLLï¼‰è¯Šæ–­æ£€æŸ¥çš„é¦–è¦æŒ‡æ ‡ã€‚CLL çš„ç»å¯¹é£é™©ä¸å¹´é¾„ã€æ€§åˆ«å’Œ ALC çš„å…³ç³»å°šæœªè¢«æè¿°ã€‚æ–¹æ³• æˆ‘ä»¬ä½¿ç”¨äº†æ¥è‡ªè‹±å›½ç”Ÿç‰©æ ·æœ¬åº“çš„ 475,399 åçºµå‘éšè®¿ç ”ç©¶å‚ä¸è€…çš„è¯Šæ–­å‰ ALC ä¿¡æ¯ï¼Œä¸­ä½éšè®¿ 11.6 å¹´ï¼Œå…¶ä¸­ 854 åå‚ä¸è€…è¢«è¯Šæ–­ä¸º CLLã€‚åŸºäºæ€§åˆ«ã€æ‹›å‹Ÿå¹´é¾„å’Œè¯Šæ–­å‰ ALC çš„çµæ´»å‚æ•°ç”Ÿå­˜æ¨¡å‹ï¼Œå»ºç«‹äº† CLL é£é™©æ¨¡å‹ã€‚ç»“æœä¸ ALC ä½äº 2 x109 ç»†èƒ/å‡çš„ç ”ç©¶å‚ä¸è€…ç›¸æ¯”ï¼ŒALC ç»†èƒæ•°ä¸º 3 è‡³ 4x109 ç»†èƒ/å‡çš„æ‚£è€…ï¼ŒCLL é£é™©å‡ ä¹é«˜å‡º 8 å€ï¼ˆå¿ƒç‡ 7.76,95%ç½®ä¿¡åŒºé—´ï¼š6.24-9.65ï¼‰ã€‚ç”·æ€§çš„ CLL ç»å¯¹é£é™©æ˜¯å¥³æ€§çš„ä¸¤å€ã€‚å¯¹äº 60 å² ALC ä¸º 5x109 ç»†èƒ/L çš„äººç¾¤ï¼Œç”·æ€§ä¼°è®¡ 10 å¹´ CLL é£é™©ä¸º 6.5%ï¼ˆ95%ç½®ä¿¡åŒºé—´ï¼š5.6%-7.5%ï¼‰ï¼Œå¥³æ€§ä¸º 3.5%ï¼ˆ3.0%-4<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1995612811164758016/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> <strong>HER2DX åŸºå› ç»„æ£€æµ‹ä¸ HER2 é˜³æ€§ä¹³è…ºç™Œç”Ÿç‰©å­¦å’Œç—…ç†ç‰¹å¾çš„å…³è”ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šåŸºå› ç»„<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: èƒŒæ™¯ HER2DX æ˜¯ä¸€ç§ç»è¿‡éªŒè¯çš„åŸºå› ç»„æ£€æµ‹æ³•ï¼Œç”¨äºæ”¯æŒæ—©æœŸ HER2 é˜³æ€§ï¼ˆHER2+ï¼‰ä¹³è…ºç™Œçš„æ²»ç–—å†³ç­–ã€‚å®ƒæä¾›ä¸‰ä¸ªè¯„åˆ†ï¼šå¤å‘é£é™©ã€ç—…ç†å®Œå…¨ååº”ï¼ˆpCRï¼‰çš„å¯èƒ½æ€§å’Œ ERBB2 mRNA è¡¨è¾¾ã€‚æœ¬ç ”ç©¶æ—¨åœ¨è¯„ä¼° HER2DX ä¸ç»„ç»‡ç—…ç†ç‰¹å¾ä¹‹é—´çš„å…³è”ï¼Œå¹¶è¯„ä¼°å…¶ä¸æ–°è¾…åŠ©ç–—æ³•å pCR çš„å…³ç³»ã€‚æ–¹æ³• åœ¨è¥¿ç­ç‰™å¸¸è§„æŠ¤ç†æœŸé—´ï¼ˆ2022 å¹´ 1 æœˆè‡³ 2025 å¹´ 6 æœˆï¼‰ï¼Œæ ¹æ®ç°æœ‰ HER2DX ç»“æœåˆ†æäº†æ–°è¯Šæ–­çš„ I-III æœŸ HER2+ä¹³è…ºç™Œæ‚£è€…ã€‚é›†ä¸­ HER2DX æ£€æµ‹å¯¹å›ºå®šç¦é©¬æ—ã€çŸ³èœ¡åµŒå…¥çš„è‚¿ç˜¤æ ·æœ¬è¿›è¡Œäº†ã€‚ç»„ç»‡ç—…ç†å­¦åˆ†æåŒ…æ‹¬è‚¿ç˜¤ç­‰çº§ã€æ¿€ç´ å—ä½“ï¼ˆHRï¼‰çŠ¶æ€ã€ç»„ç»‡å­¦äºšå‹ã€Ki67 æŒ‡æ•°ã€HER2 å…ç–«ç»„åŒ–ï¼ˆIHCï¼‰è¯„åˆ†ã€é—´è´¨è‚¿ç˜¤æµ¸æ¶¦æ·‹å·´ç»†èƒï¼ˆTILsï¼‰ã€ä¸‰çº§æ·‹å·´ç»“æ„ï¼ˆTLSï¼‰åŠç©ºé—´å…ç–«åˆ†å¸ƒã€‚è¿›è¡Œäº†å•å˜é‡å’Œå¤šå˜é‡é€»è¾‘å›å½’åˆ†æï¼Œä»¥è¯†åˆ«æ–°è¾…åŠ©æ›²å¦¥ç å•æŠ—æ²»ç–—å pCR ç›¸å…³çš„å› ç´ ã€‚ç»“æœ å…±åˆ†æ 410<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1995612813853306880/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> <strong>åœ¨æºå¸¦ PIK3CA çªå˜çš„ HER2 é˜³æ€§è½¬ç§»æ€§ä¹³è…ºè‚¿ç˜¤ä¸­ï¼Œå°† ipatasertib åŠ å…¥åŒé‡æŠ— HER2 ç»´æŒæ²»ç–—ï¼š1b æœŸ SOLTI-1507 IPATHER è¯•éªŒã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: ç›®çš„ è¯„ä¼°ä¼Šå¸•æ‰˜è¥¿å¸ƒè”åˆæ›²å¦¥ç å•æŠ—å’Œæ´¾å¦¥ç¥–å•æŠ—ä½œä¸º HER2 é˜³æ€§è½¬ç§»æ€§ä¹³è…ºç™Œæ‚£è€…åœ¨ä¸€çº¿æ²»ç–—åç»´æŒæ²»ç–—çš„å®‰å…¨æ€§å’Œå¯è¡Œæ€§ï¼Œé€‚ç”¨äºæºå¸¦ PIK3CA çªå˜çš„ HER2 é˜³æ€§è½¬ç§»æ€§ä¹³è…ºç™Œæ‚£è€…ã€‚å®éªŒè®¾è®¡ æœ¬å‰ç»æ€§ã€å¤šä¸­å¿ƒã€å•è‡‚ã€1b æœŸä¸´åºŠç ”ç©¶è¯„ä¼°äº† AKT æŠ‘åˆ¶å‰‚ä¼Šå¸•æ‰˜è¥¿å•æŠ—ï¼ˆipatasertibï¼‰ä¸æ›²å¦¥ç å•æŠ—ï¼ˆtrastuzumabï¼‰å’Œæ´¾å¦¥ç¥–å•æŠ—ï¼ˆHPï¼‰è”åˆä½¿ç”¨ï¼Œé…åˆæˆ–ä¸ä½¿ç”¨å†…åˆ†æ³Œæ²»ç–—ä½œä¸ºç»´æŒç–—æ³•çš„å®‰å…¨æ€§å’Œåˆæ­¥ç–—æ•ˆï¼Œé€‚ç”¨äºä¸€çº¿è¯±å¯¼åŒ–ç–—å’Œ HP åä¸å¯åˆ‡é™¤çš„å±€éƒ¨æ™šæœŸæˆ–è½¬ç§»æ€§ PIK3CAmutã€HER2 é˜³æ€§ä¹³è…ºç™Œæ‚£è€…ã€‚ç»“æœ å…±çº³å…¥ 17 ä¾‹æ‚£è€…ï¼Œ ä¸­ä½éšè®¿æ—¶é—´ä¸º 27.7 ä¸ªæœˆã€‚åœ¨å‰‚é‡é€‰æ‹©é˜¶æ®µï¼Œä¾å¸•æ‰˜æ²™æ›¿å¸ƒæ¯æ—¥ 400 æ¯«å…‹ï¼ˆ21 å¤©æœç”¨ï¼Œ7 å¤©åœè¯ï¼‰ä¸æ ‡å‡† HP å‰‚é‡è¢«ç¡®ç«‹ä¸ºæ¨èçš„ç¬¬äºŒé˜¶æ®µå‰‚é‡ï¼ˆRP2Dï¼‰ã€‚è¿™ä¸€å†³å®šåŸºäºåœ¨åˆå§‹ 28 å¤©å‘¨æœŸå†…ï¼Œå‰å…­åæ¥å—è¯¥å‰‚é‡æ²»ç–—çš„æ‚£è€…å‡æœªå‡ºç°å‰‚é‡é™åˆ¶æ€§æ¯’æ€§ï¼Œè¯¥ä¸ºä¸»è¦ç»ˆç‚¹ã€‚7<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1995612816629936128/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> <strong>è‚ é“æ£€æŸ¥ï¼šçº¦ç¿°é€Šä¹³é…¸æ†èŒåˆ©ç”¨èƒ†æ±é…¸å’Œæ´»æ€§æ°§æ¥æŠ‘åˆ¶é«˜è„‚é¥®é£Ÿå¼•èµ·çš„ç»“ç›´è‚ ç™Œã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚ é“<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: ç»“ç›´è‚ ç™Œæ˜¯å…¨çƒæœ€å¸¸è§ä¸”è‡´å‘½çš„æ¶æ€§è‚¿ç˜¤ä¹‹ä¸€ï¼Œå…¶å‘ç—…ç‡ä¸ç”Ÿæ´»æ–¹å¼å› ç´ å¯†åˆ‡ç›¸å…³ï¼ŒåŒ…æ‹¬é«˜è„‚é¥®é£Ÿï¼ˆHFDï¼‰ã€‚æµè¡Œç—…å­¦ç ”ç©¶å°†é«˜è„‚è‚ªé¥®é£Ÿä¸ç»“ç›´è‚ ç™Œé£é™©å¢åŠ ç›¸å…³ï¼Œä½†ä¸ªä½“æ˜“æ„Ÿæ€§å·®å¼‚å¾ˆå¤§ï¼Œæ½œåœ¨é©±åŠ¨å› ç´ ä»ä¸å……åˆ†ã€‚è¿‘æœŸè¿›å±•ä½¿ç ”ç©¶èŒƒå¼ä»ä»…å…³æ³¨é¥®é£Ÿç»„æˆè½¬å‘è€ƒè™‘å®¿ä¸»-å¾®ç”Ÿç‰©ç›¸äº’ä½œç”¨åŠå¾®ç”Ÿç‰©ä»£è°¢ç‰©è°±å¯¹é«˜è„‚è‚ªé¥®é£Ÿé©±åŠ¨ç»“ç›´è‚ ç™Œé£é™©çš„ä¸ªä½“å·®å¼‚è´¡çŒ®ã€‚åœ¨æœ¬æœŸã€Šç™Œç—‡ç ”ç©¶ã€‹æ‚å¿—ä¸­ï¼Œåˆ˜æ°åŠå…¶åŒäº‹ç ”ç©¶äº†çº¦ç¿°é€Šä¹³é…¸æ†èŒä½œä¸ºæŠ‘åˆ¶é«˜è„‚è›‹ç™½é©±åŠ¨è‚¿ç˜¤å‘ç”Ÿçš„ä¿æŠ¤æ€§ç»†èŒã€‚é€šè¿‡ä¿ƒè¿›å…±è½­èƒ†é…¸è½¬åŒ–ä¸ºé¡ºä¾¿åµè´¨èƒ†é…¸ï¼Œå¼ºæ£®æ°é•¿æ†èŒå¼•å‘çº¿ç²’ä½“åŠŸèƒ½éšœç¢ï¼Œä»è€Œä¿ƒè¿›æ´»æ€§æ°§ç‰©ç§çš„äº§ç”Ÿï¼Œå¹¶è¯±å¯¼å‡‹äº¡ä»¥æŠ‘åˆ¶ç»“ç›´è‚ ç™Œçš„å‘å±•ã€‚è¿™äº›ä¸´åºŠå‰å‘ç°ä¸ºèƒ†æ±é…¸ä»£è°¢ã€è‚ é“å¾®ç”Ÿç‰©ç¾¤ä¸è‡´ç™Œæœºåˆ¶çš„äº¤æ±‡æä¾›äº†æœºåˆ¶æ€§è§è§£ï¼Œå¹¶ä¸ºæœªæ¥åŸºäºç›Šç”ŸèŒçš„ç™Œç—‡é¢„é˜²è½¬åŒ–ç ”ç©¶å¥ å®šäº†åŸºç¡€ã€‚å‚è§ Liu ç­‰äººç›¸å…³æ–‡ç« ï¼Œç¬¬ 4600 é¡µã€‚<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1995608978590117888/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
</div>
</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§ª åšå®¢æ›´æ–° (1æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨1æ¡ï¼‰</h4>
<p><strong>1.</strong> <strong>é€šè¿‡RNAè¡¨è¾¾äº†è§£è‚¿ç˜¤å¼‚è´¨æ€§</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumor<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šRNA sequencing was used to evaluate tumor heterogeneity in breast cancer, revealing links to cell growth and immune activity but limited power in predicting treatment response...<br />
- ğŸ”— <a href="https://www.rna-seqblog.com/understanding-tumor-heterogeneity-through-rna-expression/" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
</div>
</details>

<h2>ğŸ“Š å…³é”®è¯ç»Ÿè®¡</h2>
<table class="keywords-table">
<thead>
<tr>
<th>å…³é”®è¯</th>
<th>å‡ºç°æ¬¡æ•°</th>
</tr>
</thead>
<tbody>
<tr>
<td>cancer</td>
<td>28</td>
</tr>
<tr>
<td>RNA-seq</td>
<td>18</td>
</tr>
<tr>
<td>histone</td>
<td>17</td>
</tr>
<tr>
<td>tumor</td>
<td>9</td>
</tr>
<tr>
<td>ChIP-seq</td>
<td>8</td>
</tr>
<tr>
<td>leukemia</td>
<td>7</td>
</tr>
<tr>
<td>metabolic</td>
<td>5</td>
</tr>
<tr>
<td>sequencing</td>
<td>5</td>
</tr>
<tr>
<td>single-cell</td>
<td>5</td>
</tr>
<tr>
<td>ATAC-seq</td>
<td>4</td>
</tr>
<tr>
<td>scRNA</td>
<td>4</td>
</tr>
<tr>
<td>immunity</td>
<td>3</td>
</tr>
<tr>
<td>pathway</td>
<td>2</td>
</tr>
<tr>
<td>methylation</td>
<td>2</td>
</tr>
<tr>
<td>immune</td>
<td>2</td>
</tr>
<tr>
<td>lymph</td>
<td>2</td>
</tr>
<tr>
<td>regex:lymph(o</td>
<td>atic)?</td>
</tr>
<tr>
<td>spatial</td>
<td>2</td>
</tr>
<tr>
<td>transcriptome</td>
<td>2</td>
</tr>
<tr>
<td>Alzheimer</td>
<td>1</td>
</tr>
</tbody>
</table>
<hr />
<h2>ğŸ“ æ›´å¤šå†…å®¹</h2>
<details>
<summary><a name="æ›´å¤š-æ•°æ®å‰æ²¿"></a>ğŸ§¬ æ•°æ®å‰æ²¿ å…¶ä»–å†…å®¹ (73æ¡)</summary>
<div class="details-content">
<ul>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293089" target="_blank" rel="noopener noreferrer">GSE293089 ç»„è›‹ç™½ç”²åŸºè½¬ç§»é…¶ KMT2D æ˜¯å»åŠ¿æŠµæŠ—æ€§å‰åˆ—è…ºç™Œè°±ç³»å¯å¡‘æ€§å’Œæ²»ç–—ååº”çš„å…³é”®ä»‹è´¨ [FOXA1 ChIP-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293080" target="_blank" rel="noopener noreferrer">GSE293080 ç»„è›‹ç™½ç”²åŸºè½¬ç§»é…¶ KMT2D æ˜¯å»åŠ¿æŠµæŠ—æ€§å‰åˆ—è…ºç™Œè°±ç³»å¯å¡‘æ€§å’Œæ²»ç–—ååº”çš„å…³é”®ä»‹è´¨ [AR ChIP-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293079" target="_blank" rel="noopener noreferrer">GSE293079 ç»„è›‹ç™½ç”²åŸºè½¬ç§»é…¶ KMT2D æ˜¯å»åŠ¿æŠµæŠ—æ€§å‰åˆ—è…ºç™Œè°±ç³»å¯å¡‘æ€§å’Œæ²»ç–—ååº”çš„å…³é”®ä»‹è´¨ [MSKPCA3 Bulk ATAC-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293067" target="_blank" rel="noopener noreferrer">GSE293067 ç»„è›‹ç™½ç”²åŸºè½¬ç§»é…¶ KMT2D æ˜¯å»åŠ¿æŠµæŠ—æ€§å‰åˆ—è…ºç™Œè°±ç³»å¯å¡‘æ€§å’Œæ²»ç–—ååº”çš„å…³é”®ä»‹è´¨ [LNCAP Bulk ATAC-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293060" target="_blank" rel="noopener noreferrer">GSE293060 ç»„è›‹ç™½ç”²åŸºè½¬ç§»é…¶ KMT2D æ˜¯å»åŠ¿æŠµæŠ—æ€§å‰åˆ—è…ºç™Œè°±ç³»å¯å¡‘æ€§å’Œæ²»ç–—ååº”çš„å…³é”®ä»‹è´¨ [DU145 Bulk RNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293025" target="_blank" rel="noopener noreferrer">GSE293025 ç»„è›‹ç™½ç”²åŸºè½¬ç§»é…¶ KMT2D æ˜¯å»åŠ¿æŠµæŠ—æ€§å‰åˆ—è…ºç™Œè°±ç³»å¯å¡‘æ€§å’Œæ²»ç–—ååº”çš„å…³é”®ä»‹è´¨ [DU145 Bulk ATAC-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290943" target="_blank" rel="noopener noreferrer">GSE290943 scRNAseq åˆ†æäº†åŸå‘æ€§é»‘è‰²ç´ ç˜¤å°é¼  BP (TyrCre-ERT2Tg/0 BrafLSL-V600E/+ Ptenlox/lox) å’Œ BPT (TyrCre-ERT2Tg/0 BrafLSL-V600E/+ Ptenlox/lox Tslp-/-) è‚¿ç˜¤å¼•æµæ·‹å·´ç»“ (tdLN) ä¸­è¿ç§»æ€§æ ‘çªçŠ¶ç»†èƒ (DC) å’Œ CD4+ T ç»†èƒçš„åˆ†å¸ƒæƒ…å†µã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311935" target="_blank" rel="noopener noreferrer">GSE311935 æ¯›ç»†èƒç™½è¡€ç—… (HCL) æ‚£è€…ç™Œç»†èƒçš„å•ç»†èƒè½¬å½•ç»„åˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311267" target="_blank" rel="noopener noreferrer">GSE311267 é¶å‘ Syndecan-1 çš„æ²»ç–—æ€§æŠ—ä½“æŠ‘åˆ¶å·¨èƒé¥®ä½œç”¨å¹¶è¯±å¯¼èƒ°è…ºç™Œçš„æŠ—è‚¿ç˜¤å…ç–«</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE298098" target="_blank" rel="noopener noreferrer">GSE298098 è¯±å¯¼å‹ CD147 ä¸Šè°ƒå¢å¼ºæŒç»­æ€§ SARS-CoV-2 æ„ŸæŸ“ï¼Œå¼•å‘é‡ç—‡ COVID-19ï¼Œä¸”ä¸ ACE2 æ— å…³ [ç©ºé—´è½¬å½•ç»„å­¦]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE230037" target="_blank" rel="noopener noreferrer">GSE230037 çŒªè„‚è‚ªç»„ç»‡çš„å•ç»†èƒè½¬å½•ç»„æµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309586" target="_blank" rel="noopener noreferrer">GSE309586 å…¨è½¬å½•æœ¬ m6A ç”²åŸºåŒ–å½±å“ä¸ä¾èµ–å¸½ç»“æ„çš„ç¿»è¯‘èµ·å§‹ [RNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE307942" target="_blank" rel="noopener noreferrer">GSE307942 äººç±»ç™½ç»†èƒä¸­CBLçš„ä½“ç»†èƒç¼ºé™·ä¼šæŸå®³Bç»†èƒè€ŒéTç»†èƒçš„å‘è‚²å’ŒåŠŸèƒ½</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE288188" target="_blank" rel="noopener noreferrer">GSE288188 è½¬å½•å› å­ NKX2-1 ä¸ RUNX1 ååŒä½œç”¨ï¼Œä¿æŠ¤ T ç»†èƒæ€¥æ€§æ·‹å·´ç»†èƒç™½è¡€ç—…ç»†èƒå…å— DNA æŸä¼¤ [ChIP-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE288187" target="_blank" rel="noopener noreferrer">GSE288187 è½¬å½•å› å­ NKX2-1 ä¸ RUNX1 ååŒä½œç”¨ï¼Œä¿æŠ¤ T ç»†èƒæ€¥æ€§æ·‹å·´ç»†èƒç™½è¡€ç—…ç»†èƒå…å— DNA æŸä¼¤ [RNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE266626" target="_blank" rel="noopener noreferrer">GSE266626 TCF3::HLF é€šè¿‡æ¿€æ´» MEF2C åè°ƒå¢å¼ºå­-å¯åŠ¨å­ç½‘ç»œï¼Œä¿ƒè¿›ç™½è¡€ç—…ä¸­æœªæˆç†Ÿ HSC åŸºå› è¡¨è¾¾ [RNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE308946" target="_blank" rel="noopener noreferrer">GSE308946 ç»„è›‹ç™½ç”²åŸºè½¬ç§»é…¶ KMT2D æ˜¯å»åŠ¿æŠµæŠ—æ€§å‰åˆ—è…ºç™Œè°±ç³»å¯å¡‘æ€§å’Œæ²»ç–—ååº”çš„å…³é”®ä»‹è´¨ [CUT&amp;Run]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296270" target="_blank" rel="noopener noreferrer">GSE296270 ç»„è›‹ç™½ç”²åŸºè½¬ç§»é…¶KMT2Dæ˜¯å»åŠ¿æŠµæŠ—æ€§å‰åˆ—è…ºç™Œè°±ç³»å¯å¡‘æ€§å’Œæ²»ç–—ååº”çš„å…³é”®ä»‹è´¨</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE291282" target="_blank" rel="noopener noreferrer">GSE291282 ç»„è›‹ç™½ç”²åŸºè½¬ç§»é…¶KMT2Dæ˜¯å»åŠ¿æŠµæŠ—æ€§å‰åˆ—è…ºç™Œè°±ç³»å¯å¡‘æ€§å’Œæ²»ç–—ååº”çš„å…³é”®ä»‹è´¨</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE278892" target="_blank" rel="noopener noreferrer">GSE278892 MC903 å¤„ç†å°é¼ çš®è‚¤å¼•æµæ·‹å·´ç»“ä¸­è¿ç§»æ€§ nLCncDC1 çš„ CITEseq</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE308702" target="_blank" rel="noopener noreferrer">GSE308702 ARMCX3 æ•²ä½çš„è½¬å½•ç»„åˆ†ææ­ç¤ºäº†ä¹³è…ºç™Œç»†èƒä¸­ p53â€“IFIH1 è½´å’Œå…ç–«é€šè·¯çš„æ¿€æ´»ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290391" target="_blank" rel="noopener noreferrer">GSE290391ï¼šå°é¼ é€ è¡€å±‚çº§ç»“æ„çš„å•ç»†èƒRNAæµ‹åºã€ULACæµ‹åºå’ŒRNAæµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311811" target="_blank" rel="noopener noreferrer">GSE311811 å¤šé‡åµŒåˆè‚¿ç˜¤æ¨¡å‹æ­ç¤ºäº†ç¾¤ä½“å†…å’Œç¾¤ä½“é—´è¯ç‰©ååº”çš„è‡ªç„¶è¡¨å‹å˜å¼‚ [scRNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE304316" target="_blank" rel="noopener noreferrer">GSE304316 æ„å»ºå¹¿è—¿é¦™èƒšçŠ¶ä½“çš„å•ç»†èƒè½¬å½•ç»„å›¾è°±ï¼Œæ­ç¤º PcNAC048 ä½œä¸ºåŒé‡è°ƒæ§å› å­ï¼Œåè°ƒä¾§æ ¹å½¢æ€å‘ç”Ÿå’Œå¹¿è—¿é¦™é†‡ç”Ÿç‰©åˆæˆã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303432" target="_blank" rel="noopener noreferrer">GSE303432 RELB é‡ç¼–ç¨‹è€—ç«­çš„è‚¿ç˜¤æµ¸æ¶¦æ·‹å·´ç»†èƒä»¥æ”¹å–„è¿‡ç»§ç»†èƒç–—æ³• [RNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE274326" target="_blank" rel="noopener noreferrer">GSE274326 IKKa é€šè¿‡é˜»æ­¢ç´§å¯†è¿æ¥ç¨³å®šå’Œé›†ä½“ç»†èƒè¿ç§»æ¥è°ƒèŠ‚ç»“ç›´è‚ ç™Œè½¬ç§» [RNA-seq PDX]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE274325" target="_blank" rel="noopener noreferrer">GSE274325 IKKa é€šè¿‡é˜»æ­¢ç´§å¯†è¿æ¥ç¨³å®šå’Œé›†ä½“ç»†èƒè¿ç§»æ¥è°ƒèŠ‚ç»“ç›´è‚ ç™Œè½¬ç§» [RNA-seq Tumoroid]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE274321" target="_blank" rel="noopener noreferrer">GSE274321 IKKa é€šè¿‡é˜»æ­¢ç´§å¯†è¿æ¥ç¨³å®šå’Œé›†ä½“ç»†èƒè¿ç§»æ¥è°ƒèŠ‚ç»“ç›´è‚ ç™Œè½¬ç§» [scRNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310670" target="_blank" rel="noopener noreferrer">GSE310670 TCF3::HLF é€šè¿‡æ¿€æ´» MEF2C åè°ƒå¢å¼ºå­-å¯åŠ¨å­ç½‘ç»œï¼Œä¿ƒè¿›ç™½è¡€ç—…ä¸­æœªæˆç†Ÿ HSC åŸºå› è¡¨è¾¾ç¨‹åºã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310669" target="_blank" rel="noopener noreferrer">GSE310669 TCF3::HLF é€šè¿‡æ¿€æ´» MEF2C åè°ƒå¢å¼ºå­-å¯åŠ¨å­ç½‘ç»œï¼Œä»è€Œä¿ƒè¿›ç™½è¡€ç—…ä¸­æœªæˆç†Ÿ HSC åŸºå› è¡¨è¾¾ç¨‹åºã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309588" target="_blank" rel="noopener noreferrer">GSE309588 å…¨è½¬å½•æœ¬ m6A ç”²åŸºåŒ–å½±å“ä¸ä¾èµ–å¸½ç»“æ„çš„ç¿»è¯‘èµ·å§‹ [Ribo-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296077" target="_blank" rel="noopener noreferrer">GSE296077 äººç±»ç¥ç»å…ƒåˆ†åŒ–è¿‡ç¨‹ä¸­çš„ä»£è°¢é‡ç¼–ç¨‹æ­ç¤ºè°·æ°¨é…°èƒºé…¶æ˜¯è„†æ€§Xç»¼åˆå¾çš„å…³é”®å†³å®šå› ç´ </a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE278790" target="_blank" rel="noopener noreferrer">GSE278790 PDX1 ç£·é…¸åŒ–ä»‹å¯¼èƒ°å²›Î²ç»†èƒä¸­çš„æ°¨åŸºé…¸-mTORC1 ä¿¡å·ä¼ å¯¼ [RNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE278789" target="_blank" rel="noopener noreferrer">GSE278789 PDX1 ç£·é…¸åŒ–ä»‹å¯¼èƒ°è…º Î² ç»†èƒä¸­çš„æ°¨åŸºé…¸-mTORC1 ä¿¡å·ä¼ å¯¼ [ChIP-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE266625" target="_blank" rel="noopener noreferrer">GSE266625 TCF3::HLF é€šè¿‡æ¿€æ´» MEF2C åè°ƒå¢å¼ºå­-å¯åŠ¨å­ç½‘ç»œï¼Œä¿ƒè¿›ç™½è¡€ç—…ä¸­æœªæˆç†Ÿ HSC åŸºå› è¡¨è¾¾ [HiChIP]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311806" target="_blank" rel="noopener noreferrer">GSE311806 è†³é£Ÿç›æŸå®³ç›æ•æ„Ÿæ€§é«˜è¡€å‹æ‚£è€…çš„æ˜¼å¤œèŠ‚å¾‹ç”Ÿç†ä»£è°¢é€‚åº”</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE304330" target="_blank" rel="noopener noreferrer">GSE304330 RNAæµ‹åºæ­ç¤ºäº†é“œç»¿å‡å•èƒèŒç”Ÿé•¿é˜¶æ®µç‰¹å¼‚æ€§çš„æ•´ä½“è½¬å½•ä½“æ¸©è°ƒèŠ‚å·®å¼‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE304229" target="_blank" rel="noopener noreferrer">GSE304229 RNA-seq æ•°æ®æ¥è‡ªåœ¨ 37Â°C æˆ– 25Â°C ä¸‹åŸ¹å…»è‡³ç¨³å®šæœŸçš„ PAO1 å’Œ Î”lasR èŒæ ªã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE304114" target="_blank" rel="noopener noreferrer">GSE304114 PAO1 åœ¨ä¸¤ç§æ¸©åº¦å’Œä¸¤ä¸ªç”Ÿé•¿é˜¶æ®µçš„ RNA-seq</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE295016" target="_blank" rel="noopener noreferrer">GSE295016 TREM2 è¡¨è¾¾æ°´å¹³å¯¹å°èƒ¶è´¨ç»†èƒçŠ¶æ€ã€ä»£è°¢èƒ½åŠ›å’Œ TREM2 æ¿€åŠ¨å‰‚çš„åŠŸæ•ˆè‡³å…³é‡è¦ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE291343" target="_blank" rel="noopener noreferrer">GSE291343 é›„æ€§è‚¾ä¸Šè…ºçš®è´¨ç±»å›ºé†‡ç”Ÿæˆè°±ç³»çš„å•ç»†èƒRNAæµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE284496" target="_blank" rel="noopener noreferrer">GSE284496 å°é¼ èƒšèƒæ™šæœŸå’Œå‡ºç”Ÿæ—©æœŸè‚¾è„çš„å•æ ¸ RNA æµ‹åºã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE283722" target="_blank" rel="noopener noreferrer">GSE283722 SGLT2æŠ‘åˆ¶å‰‚æ©æ ¼åˆ—å‡€å¢å¼ºè‚Œçƒè›‹ç™½R403Qçªå˜è‚¥åšå‹å¿ƒè‚Œç—…å°é¼ çš„ä»£è°¢æ•ˆç‡å¹¶æ”¹å–„å·¦å¿ƒå®¤è‚¥åš</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE282712" target="_blank" rel="noopener noreferrer">GSE282712 æ–°ç”Ÿå°é¼ è„‘å†…å…ˆå¤©æ€§å·¨ç»†èƒç—…æ¯’æ„ŸæŸ“çš„å•ç»†èƒåˆ†è¾¨ç‡åˆ†å­ç‰¹å¾</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE281413" target="_blank" rel="noopener noreferrer">GSE281413 æ—©å‘å‹å’Œä¸­å‘å‹ç»“ç›´è‚ ç™ŒåŠå…¶åŒ¹é…çš„æ­£å¸¸ç»“è‚ ç»„ç»‡</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE277899" target="_blank" rel="noopener noreferrer">GSE277899 å¯¹æ„ŸæŸ“é¸Ÿåˆ†ææ†èŒå››å‘¨çš„é‡ç”Ÿå‹ HSCã€MPP3ã€GMP å’Œå·¨å™¬ç»†èƒè¿›è¡Œ CUT&amp;RUN æµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE271074" target="_blank" rel="noopener noreferrer">GSE271074 TREM2è¡¨è¾¾æ°´å¹³å¯¹å°èƒ¶è´¨ç»†èƒçŠ¶æ€ã€ä»£è°¢èƒ½åŠ›å’ŒTREM2æ¿€åŠ¨å‰‚çš„ç–—æ•ˆè‡³å…³é‡è¦</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311914" target="_blank" rel="noopener noreferrer">GSE311914ï¼šäºŒç¡«è…™å¤„ç†å°é¼ æ½˜æ°ç»†èƒåï¼Œè‚ ä¸Šçš®ç»†èƒæ¥æºçš„ç»†èƒå¤–å›Šæ³¡çš„ miRNA è¡¨è¾¾è°±åˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290390" target="_blank" rel="noopener noreferrer">GSE290390 å°é¼ é€ è¡€å±‚çº§çš„å…¨å±€mRNAè°±åˆ†æï¼ˆRNA-seqï¼‰</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290388" target="_blank" rel="noopener noreferrer">GSE290388ï¼šNat10ç¼ºå¤±åå°é¼ é€ è¡€å¹²ç»†èƒçš„å•ç»†èƒè½¬å½•ç»„åˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE269664" target="_blank" rel="noopener noreferrer">GSE269664 ç”¨äºé¶å‘é™è§£ MYC å’Œ KRAS çš„å¼‚åŒåŠŸèƒ½è›‹ç™½æ¨¡æ‹Ÿèšåˆç‰©</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311917" target="_blank" rel="noopener noreferrer">GSE311917 å‡‹äº¡ç»†èƒæ¸…é™¤è§¦å‘å‰åˆ—è…ºé€€åŒ–è¿‡ç¨‹ä¸­ä¸Šçš®ç»†èƒå‘½è¿é‡ç¼–ç¨‹ [ChIP-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311846" target="_blank" rel="noopener noreferrer">GSE311846 éå°ç»†èƒè‚ºç™Œä¸­çº¿ç²’ä½“åŒé“¾RNAä¾èµ–æ€§è„‚è´¨é‡ç¼–ç¨‹</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311813" target="_blank" rel="noopener noreferrer">GSE311813 å¤šé‡åµŒåˆè‚¿ç˜¤æ¨¡å‹æ­ç¤ºäº†ç¾¤ä½“å†…å’Œç¾¤ä½“é—´è¯ç‰©ååº”çš„è‡ªç„¶è¡¨å‹å˜å¼‚[å¼‚ç§ç§»æ¤]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311810" target="_blank" rel="noopener noreferrer">GSE311810 å¤šé‡åµŒåˆè‚¿ç˜¤æ¨¡å‹æ­ç¤ºäº†ç¾¤ä½“å†…å’Œç¾¤ä½“é—´è¯ç‰©ååº”çš„è‡ªç„¶è¡¨å‹å˜å¼‚ [CRISPR ç­›é€‰]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311794" target="_blank" rel="noopener noreferrer">GSE311794 è·¨è†œè›‹ç™½åŠŸèƒ½ç­›é€‰é‰´å®šå‡ºå¤šèœé†‡ç„¦ç£·é…¸ç£·é…¸é…¶ CAX-4 æ˜¯ç²—ç³™è„‰å­¢èŒä¸­éº¦è§’ç”¾é†‡ç”Ÿç‰©åˆæˆå’Œå”‘ç±»è€è¯æ€§çš„å…³é”®è°ƒæ§å› å­</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311745" target="_blank" rel="noopener noreferrer">GSE311745 åŸºäºç©ºé—´è½¬å½•ç»„å­¦çš„IgAè‚¾ç—…å†…æ¯›ç»†è¡€ç®¡å†…ç»†èƒå¢ç”Ÿ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311711" target="_blank" rel="noopener noreferrer">GSE311711 ç‰™é¾ˆæˆçº¤ç»´ç»†èƒæš´éœ²äºæ´»åŒ–è¡€å°æ¿çš„ RNA æµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311707" target="_blank" rel="noopener noreferrer">GSE311707 ç¡¬åº¦ä»‹å¯¼çš„æ—åˆ†æ³Œä¿¡å·å¢å¼ºå£è…”é³çŠ¶ç»†èƒç™Œä¸­ä¸Šçš®é—´è´¨è½¬åŒ–ï¼ˆEMTï¼‰çš„è¯±å¯¼</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303442" target="_blank" rel="noopener noreferrer">GSE303442 RELB é‡ç¼–ç¨‹è€—ç«­çš„è‚¿ç˜¤æµ¸æ¶¦æ·‹å·´ç»†èƒä»¥æ”¹å–„è¿‡ç»§ç»†èƒç–—æ³•[å¢æ®–]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303438" target="_blank" rel="noopener noreferrer">GSE303438 RELB é‡ç¼–ç¨‹è€—ç«­çš„è‚¿ç˜¤æµ¸æ¶¦æ·‹å·´ç»†èƒä»¥æ”¹å–„è¿‡ç»§ç»†èƒç–—æ³• [TCR-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE302983" target="_blank" rel="noopener noreferrer">GSE302983 é¶å‘å‰åˆ—è…ºç™Œä¸­å·²å­˜åœ¨çš„æ£’çŠ¶ç»†èƒå¯å¢å¼ºé›„æ¿€ç´ å‰¥å¤ºç–—æ³•çš„æ•ˆæœ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE300781" target="_blank" rel="noopener noreferrer">GSE300781 C13 ç»†èŒç¾¤è½å¯¹ç©ºè‚ å¼¯æ›²èŒæ„ŸæŸ“æ•æ„Ÿï¼Œè¿™ä¼šå½±å“é¶å‘ç»†èŒå’Œå®¿ä¸»åŸºå› çš„å®¿ä¸»æ¥æº miRNAã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE298097" target="_blank" rel="noopener noreferrer">GSE298097 è¯±å¯¼å‹ CD147 ä¸Šè°ƒå¢å¼ºæŒç»­æ€§ SARS-CoV-2 æ„ŸæŸ“ï¼Œå¼•å‘é‡ç—‡ COVID-19ï¼Œä¸”ä¸ ACE2 æ— å…³ [scRNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE284367" target="_blank" rel="noopener noreferrer">GSE284367 æŠ‘åˆ¶æ•´åˆåº”æ¿€ååº”é€šâ€‹â€‹è¿‡ mTOR é€šè·¯ä¿ƒè¿›åŸå§‹åµæ³¡æ´»åŒ–</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE282999" target="_blank" rel="noopener noreferrer">GSE282999 æ£‰èŠ±èƒšç è¡¨çš®æ—©æœŸçº¤ç»´å‘è‚²è¿‡ç¨‹ä¸­æŸ“è‰²è´¨å¯åŠæ€§çš„å•ç»†èƒåˆ†æ [scATAC-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE274368" target="_blank" rel="noopener noreferrer">GSE274368 IKKa é€šè¿‡æŠ‘åˆ¶ç´§å¯†è¿æ¥ç¨³å®šå’Œç»†èƒé›†ä½“è¿ç§»æ¥è°ƒèŠ‚ç»“ç›´è‚ ç™Œè½¬ç§»</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE273832" target="_blank" rel="noopener noreferrer">GSE273832 ROSæ¿€æ´»NETsé‡Šæ”¾éª¨é«“CD55+ä¸­æ€§ç²’ç»†èƒï¼Œä¿ƒè¿›éª¨éª¼æ—©æœŸè€åŒ–</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE271019" target="_blank" rel="noopener noreferrer">GSE271019 å°é¼ è„‘ä¸­çš„ RNA ä¿®é¥°ã€å¯å˜å‰ªæ¥å’Œç¯çŠ¶ RNA å›¾è°±ï¼šè‚Œè‹·åŠå…¶ä»– [RNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE262356" target="_blank" rel="noopener noreferrer">GSE262356 åŒ…è£¹å“ºä¹³åŠ¨ç‰©ç»†èƒçš„å°å‹éç¼–ç RNAä¿ƒè¿›å…ˆå¤©å…ç–«</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE252429" target="_blank" rel="noopener noreferrer">GSE252429 åŒ…è£¹å“ºä¹³åŠ¨ç‰©ç»†èƒçš„å°å‹éç¼–ç RNAä¿ƒè¿›å…ˆå¤©å…ç–«</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE246570" target="_blank" rel="noopener noreferrer">GSE246570 è¡€çº¢ç´ åŠ æ°§é…¶-1å¯¹è‚¾è„ä¸­å¿ƒç¢³ä»£è°¢çš„æ§åˆ¶</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE195999" target="_blank" rel="noopener noreferrer">GSE195999 è§£å†»åéª¨é«“é—´å……è´¨å¹²ç»†èƒçš„å•ç»†èƒæµ‹åº</a></li>
</ul>
</div>
</details>

<hr />
<p><em>ğŸ“… æŠ¥å‘Šç”Ÿæˆæ—¶é—´ï¼š2025-12-02 21:35</em><br />
<em>ğŸ¤– ç”± GitHub Actions è‡ªåŠ¨ç”Ÿæˆ</em></p>
    </div>
</body>
</html>